受强制性开放获取政策约束的文章 - Kohei Shitara了解详情
无法在其他位置公开访问的文章：2 篇
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 …
YY Janjigian, A Kawazoe, Y Bai, J Xu, S Lonardi, JP Metges, P Yanez, ...
The Lancet 402 (10418), 2197-2208, 2023
强制性开放获取政策： US National Institutes of Health
INTEGRATE IIa phase III study: Regorafenib for refractory advanced gastric cancer
N Pavlakis, K Shitara, K Sjoquist, A Martin, A Jaworski, N Tebbutt, ...
Journal of Clinical Oncology, JCO. 24.00055, 2024
强制性开放获取政策： National Health and Medical Research Council, Australia
可在其他位置公开访问的文章：35 篇
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised …
YY Janjigian, K Shitara, M Moehler, M Garrido, P Salman, L Shen, ...
The Lancet 398 (10294), 27-40, 2021
强制性开放获取政策： US National Institutes of Health, Federal Ministry of Education and Research …
Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial
CS Fuchs, T Doi, RW Jang, K Muro, T Satoh, M Machado, W Sun, SI Jalal, ...
JAMA oncology 4 (5), e180013-e180013, 2018
强制性开放获取政策： US National Institutes of Health
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
YY Janjigian, A Kawazoe, P Yañez, N Li, S Lonardi, O Kolesnik, ...
Nature 600 (7890), 727-730, 2021
强制性开放获取政策： US National Institutes of Health
Assessment of pembrolizumab therapy for the treatment of microsatellite instability–high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE …
J Chao, CS Fuchs, K Shitara, J Tabernero, K Muro, E Van Cutsem, ...
JAMA oncology 7 (6), 895-902, 2021
强制性开放获取政策： US National Institutes of Health
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
K Shitara, JA Ajani, M Moehler, M Garrido, C Gallardo, L Shen, ...
Nature 603 (7903), 942-948, 2022
强制性开放获取政策： US National Institutes of Health
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised …
CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ...
The Lancet Oncology 20 (3), 420-435, 2019
强制性开放获取政策： German Research Foundation
Zolbetuximab plus CAPOX in CLDN18. 2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
MA Shah, K Shitara, JA Ajani, YJ Bang, P Enzinger, D Ilson, F Lordick, ...
Nature medicine 29 (8), 2133-2141, 2023
强制性开放获取政策： US National Institutes of Health
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis
K Oba, X Paoletti, S Alberts, YJ Bang, J Benedetti, H Bleiberg, P Catalano, ...
Journal of the National Cancer Institute 105 (21), 1600-1607, 2013
强制性开放获取政策： US National Institutes of Health
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
HC Chung, YJ Bang, C S Fuchs, SK Qin, T Satoh, K Shitara, J Tabernero, ...
Future Oncology 17 (5), 491-501, 2021
强制性开放获取政策： US National Institutes of Health
Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline
MA Shah, EB Kennedy, AE Alarcon-Rozas, T Alcindor, AN Bartley, ...
Journal of Clinical Oncology 41 (7), 1470-1491, 2023
强制性开放获取政策： US Department of Defense, US National Institutes of Health
Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of …
HH Yoon, Z Jin, O Kour, LAK Fonkoua, K Shitara, MK Gibson, LJ Prokop, ...
JAMA oncology 8 (10), 1456-1465, 2022
强制性开放获取政策： US National Institutes of Health
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—focus on proactive monitoring, diagnosis, and management
SM Swain, M Nishino, LH Lancaster, BT Li, AG Nicholson, BJ Bartholmai, ...
Cancer treatment reviews 106, 102378, 2022
强制性开放获取政策： US National Institutes of Health
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis
X Paoletti, K Oba, YJ Bang, H Bleiberg, N Boku, O Bouché, P Catalano, ...
Journal of the National Cancer Institute 105 (21), 1667-1670, 2013
强制性开放获取政策： US National Institutes of Health
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study
PM Kasi, D Kotani, M Cecchini, K Shitara, A Ohtsu, RK Ramanathan, ...
BMC cancer 16, 1-7, 2016
强制性开放获取政策： US National Institutes of Health
First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in patients with advanced solid tumors
A Shimomura, N Yamamoto, S Kondo, Y Fujiwara, S Suzuki, N Yanagitani, ...
Molecular cancer therapeutics 18 (3), 531-540, 2019
强制性开放获取政策： Cancer Research UK
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma
SJ Klempner, KW Lee, K Shitara, JP Metges, S Lonardi, DH Ilson, N Fazio, ...
Clinical Cancer Research 29 (19), 3882-3891, 2023
强制性开放获取政策： US National Institutes of Health
Efficacy and safety of trifluridine/tipiracil treatment in patients with metastatic gastric cancer who had undergone gastrectomy: subgroup analyses of a randomized clinical trial
DH Ilson, J Tabernero, A Prokharau, HT Arkenau, M Ghidini, K Fujitani, ...
JAMA oncology 6 (1), e193531-e193531, 2020
强制性开放获取政策： US National Institutes of Health
Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/oesophageal adenocarcinoma (CheckMate 649 …
YY Janjigian, K Shitara, M Moehler, M Garrido, P Salman, L Shen, ...
Lancet (London, England) 398 (10294), 27, 2021
强制性开放获取政策： US National Institutes of Health, Federal Ministry of Education and Research …
出版信息和资助信息由计算机程序自动确定